Advancing percutaneous coronary intervention

Although there have been significant advancements in diagnosing and treating coronary artery disease (CAD), it remains the leading cause of death globally and in Sweden. Treatment of CAD involves pharmacological risk- modifying therapies such as statins, aspirin/p2y12 inhibitors, and mechanical interventions aiming at improving blood flow to the myocardium. In Sweden, percutaneous coronary intervention (PCI) is performed in over 90% of patients undergoing revascularization and has been shown to improve outcomes in patients with acute coronary syndrome and reduce symptoms in those with chronic coronary syndrome. Despite advances in PCI, including the use of newer stents and improved periprocedural pharmacological treatments, outcomes have remained unchanged over the past 14 years. As a result, this thesis aims to increase knowledge and optimize treatment with PCI to improve outcomes for patients with CAD.